- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Alpharetta Today
By the People, for the People
Kuros Biosciences Reports 51% Sales Increase in Q1 2026
Strong growth in minimally invasive surgery and extremities segments drives revenue and profitability
Apr. 14, 2026 at 5:19am
Got story updates? Submit your updates here. ›
Kuros Biosciences' innovative bone healing technologies are driving strong financial and operational performance in 2026.Alpharetta TodayKuros Biosciences, a leader in next-generation bone healing technologies, announced a 51% year-over-year increase in total product sales to $43.4 million in the first three months of 2026. The company's flagship MagnetOs bone graft product saw a 51% jump in direct sales to $42.9 million, while group EBITDA reached $2.9 million and adjusted EBITDA climbed to $5.7 million.
Why it matters
Kuros's robust financial performance in Q1 2026 reflects the growing adoption of its MagnetOs technology across a diverse range of surgical applications, including minimally invasive procedures and extremities. This diversification strategy has enabled the company to capitalize on strong demand and expand its footprint beyond traditional open spine surgeries.
The details
The company's commercial execution remained strong in the first quarter, with significant progress in its extremities segment and continued growth of MagnetOs in minimally invasive surgeries. A new retrospective study also demonstrated an 87% fusion rate for MagnetOs Easypack Putty in a high-risk patient population, providing real-world evidence of the product's performance. Kuros is also making progress on its global manufacturing expansion, with its new U.S. facility in Alpharetta, Georgia, on track to begin production in the second half of 2026.
- Kuros reported Q1 2026 financial results on April 14, 2026.
- The company's new U.S. manufacturing facility in Alpharetta, Georgia, is expected to be operational in the second half of 2026.
- A retrospective study on MagnetOs Easypack Putty was published in Spine Open in 2026.
The players
Kuros Biosciences
A leader in next-generation bone healing technologies, with operations in the U.S., Switzerland, and the Netherlands.
Chris Fair
Chief Executive Officer of Kuros Biosciences.
Mark Eskander, MD
Orthopedic Spine Surgeon who led a retrospective study on MagnetOs Easypack Putty, published in Spine Open.
What they’re saying
“Kuros is off to a strong start in 2026, building on the momentum following a record-breaking 2025. Our commercial execution remained strong in the first quarter, and we delivered USD 43.4 million in product sales, EBITDA of USD 2.9 million and adjusted EBITDA of USD 5.7 million.”
— Chris Fair, Chief Executive Officer of Kuros Biosciences
What’s next
Kuros's new U.S. manufacturing facility in Alpharetta, Georgia, is expected to begin production in the second half of 2026, which will help reduce supply chain risk and strengthen the company's proximity to key U.S. markets.
The takeaway
Kuros's strong financial performance in Q1 2026, driven by growing adoption of its MagnetOs technology across diverse surgical applications, demonstrates the company's ability to capitalize on market demand and execute on its diversification strategy. The positive clinical data and manufacturing expansion further bolster Kuros's position as a leader in the bone healing technology space.
